PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 28, 2014JNCI Journal of the National Cancer Institute1,541 citationsOpen Access

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

View Full Paper
NHNadia HowladerSASean F. AltekruseCLChristopher I. Li

Key Points

Key points are not available for this paper at this time.

Abstract

In the future, SEER data can be used to monitor clinical outcomes in women diagnosed with different molecular subtypes of breast cancer for a large portion (approximately 28%) of the US population.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Howlader et al. (2014) studied this question.

synapsesocial.com/papers/69d7af6eb1cb92dd1bb8bb27https://doi.org/10.1093/jnci/dju055
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Unabridged Version)2010 · 1,056 citations
  2. 2Lessons from the neoadjuvant setting on how best to choose adjuvant therapies2011 · 27 citations
  3. 3Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups2010 · 173 citations
  4. 4Ki67 expression in breast cancer2016 · 4,397 citations
  5. 5Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades2012 · 252 citations